| 摘要 |
1. A compound of the formula I or a pharmaceutically acceptable salt thereof, wherein: R is cyclopentyl or cyclohexyl; R1 is C1-C2 alkyl, and R2 is a grouping selected from the group, consisting from the groupings of formulas from (1.1) to (1.12) 2. The compound of Claim 1 wherein R2 is a grouping of formula (l.1). 3. The compound of Claim 1 wherein R2 is a grouping of formula (l.10). 4. The compound of Claim 1 wherein R2 is a grouping of formula (l.6). 5. The compound of Claim 1 wherein R2 is a grouping of formula (l.5). 6. The compound of Claim 1 wherein R2 is a grouping of formula (l.3). 7. The compound of Claim 1, selected from the group consisting of: racemic 4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-pyrrolidine-2-one; (+)-4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-pyrrolidine-2-one; (-)4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-pyrrolidine-2-one; and pharmaceutically acceptable salts of said compounds. 8. The compound of Claim 1 selected from the group consisting of: racemic 4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)-pyrrolidine-2-one; (+)-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)-pyrrolidine-2-one; (-)-4-(1-cyclohexyl-3-ethyl-lH-indazol-6-yl)-pyrrolidine-2-one; and pharmaceutically acceptable salts of said compounds. 9. The compound of Claim 1 wherein R is cyclopentyl. 10. The compound of Claim 1 wherein R is cyclohexyl. 11. The compound of Claim 1 wherein R1 is ethyl. 12. A pharmaceutical composition for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal comprising a therapeutically-effective amount of the compound of Claim 1 and a pharmaceutically acceptable carrier. 13. A method for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal which comprises administering to said mammal a therapeutically-effective amount of the compound of Claim 1. |
